GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Ra Pharmaceuticals Inc (NAS:RARX) » Definitions » Operating Margin %

Ra Pharmaceuticals (Ra Pharmaceuticals) Operating Margin % : 0.00% (As of Dec. 2019)


View and export this data going back to 2016. Start your Free Trial

What is Ra Pharmaceuticals Operating Margin %?

Operating Margin % is calculated as Operating Income divided by its Revenue. Ra Pharmaceuticals's Operating Income for the three months ended in Dec. 2019 was $-37.83 Mil. Ra Pharmaceuticals's Revenue for the three months ended in Dec. 2019 was $0.00 Mil. Therefore, Ra Pharmaceuticals's Operating Margin % for the quarter that ended in Dec. 2019 was 0.00%.

The historical rank and industry rank for Ra Pharmaceuticals's Operating Margin % or its related term are showing as below:


RARX's Operating Margin % is not ranked *
in the Biotechnology industry.
Industry Median: -169.17
* Ranked among companies with meaningful Operating Margin % only.

Ra Pharmaceuticals's 5-Year Average Operating Margin % Growth Rate was 0.00% per year.

Ra Pharmaceuticals's Operating Income for the three months ended in Dec. 2019 was $-37.83 Mil. Its Operating Income for the trailing twelve months (TTM) ended in Dec. 2019 was $-106.98 Mil.


Ra Pharmaceuticals Operating Margin % Historical Data

The historical data trend for Ra Pharmaceuticals's Operating Margin % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Ra Pharmaceuticals Operating Margin % Chart

Ra Pharmaceuticals Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19
Operating Margin %
Get a 7-Day Free Trial -326.23 -568.67 - -2,655.52 -3,565.97

Ra Pharmaceuticals Quarterly Data
Dec14 Sep15 Dec15 Mar16 Jun16 Sep16 Dec16 Mar17 Jun17 Sep17 Dec17 Mar18 Jun18 Sep18 Dec18 Mar19 Jun19 Sep19 Dec19
Operating Margin % Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -666.36 - - -873.87 -

Competitive Comparison of Ra Pharmaceuticals's Operating Margin %

For the Biotechnology subindustry, Ra Pharmaceuticals's Operating Margin %, along with its competitors' market caps and Operating Margin % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Ra Pharmaceuticals's Operating Margin % Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Ra Pharmaceuticals's Operating Margin % distribution charts can be found below:

* The bar in red indicates where Ra Pharmaceuticals's Operating Margin % falls into.



Ra Pharmaceuticals Operating Margin % Calculation

Operating Margin % - also known as operating income margin, operating profit margin and return on sales (ROS) - is the ratio of Operating Income divided by net sales or Revenue, usually presented in percent.

Ra Pharmaceuticals's Operating Margin % for the fiscal year that ended in Dec. 2019 is calculated as

Operating Margin %=Operating Income (A: Dec. 2019 ) / Revenue (A: Dec. 2019 )
=-106.979 / 3
=-3,565.97 %

Ra Pharmaceuticals's Operating Margin % for the quarter that ended in Dec. 2019 is calculated as

Operating Margin %=Operating Income (Q: Dec. 2019 ) / Revenue (Q: Dec. 2019 )
=-37.828 / 0
= %

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Ra Pharmaceuticals  (NAS:RARX) Operating Margin % Explanation

Just like Gross Margin %, it is important to see a company maintains its operating margin over time. Among the same industry, a company with higher operating margin is more efficient in its operation. It is also more stable during industry slowdown or recessions. Peter Lynch prefers those with higher margins than those with lower margins.


Be Aware

Operating Margin % can be manipulated by adjusting the rate of depreciation, depletion and amortization (DDA).

If a company is facing competition, its Operating Margin % may decline. Often the Operating Margin % declines well before the company's Revenue or even profit decline. Therefore, Operating Margin % is a very important indicator of whether the company is facing problems.

For instance, by 2012, Nokia (NOK)'s problems were well known and its stock had lost more than 90% of its market value since 2007. But Nokia’s Operating Margin % had already been in decline since 2002, although its Earnings per Share (Diluted) were still rising. Investors who paid attention to Operating Margin % would have avoided this huge loss. The same can be said for Research-in-Motion (RIMM).

Therefore, Operating Margin % is a very important screening filter for GuruFocus. GuruFocus's Buffett-Munger screener requires that the profit margin is either consistent or expanding. The Model Portfolio of the Buffett-Munger screener has outperformed the market every year since inception in 2009.


Ra Pharmaceuticals Operating Margin % Related Terms

Thank you for viewing the detailed overview of Ra Pharmaceuticals's Operating Margin % provided by GuruFocus.com. Please click on the following links to see related term pages.


Ra Pharmaceuticals (Ra Pharmaceuticals) Business Description

Traded in Other Exchanges
N/A
Address
87 Cambridge Park Drive, Cambridge, MA, USA, 02140
Ra Pharmaceuticals Inc is a clinical-stage biopharmaceutical company. It discovers and develops therapeutics for the treatment of diseases caused by excessive or uncontrolled activation of the complement system. Geographically business of the firm can be seen amplifying in the United States, Europe and even at international level.
Executives
Peter Kolchinsky director, 10 percent owner 200 BERKELEY STREET, 18TH FLOOR, BOSTON MA 02116
Edward T Mathers director C/O MEDIMMUNE, INC., ONE MEDIMMUNE WAY, GAITHERSBURG MD 20878
Timothy R Pearson director C/O TESARO, INC., 1000 WINTER STREET, SUITE 3300, WALTHAM MA 02451
Aoife Brennan director 200 SIDNEY STREET, SUITE 320, C/O SYNLOGIC, INC., CAMBRIDGE MA 02139
Douglas A Treco director, officer: President and CEO 87 CAMBRIDGEPARK DRIVE, C/O RA PHARMACEUTICALS, INC., CAMBRIDGE MA 02140
Nea Partners 13, Limited Partnership 10 percent owner 1119 ST. PAUL STREET, BALTIMORE MD 21202
Nea 13 Gp, Ltd 10 percent owner 1119 ST. PAUL STREET, BALTIMORE MD 21202
New Enterprise Associates 13 Lp 10 percent owner 1119 ST PAUL STREET, BALTIMORE MD 21202
Rajeev M. Shah director, 10 percent owner 200 BERKELEY STREET, 18TH FLOOR, BOSTON MA 02116
Alexander Cumbo director 215 FIRST STREET, SUITE 415, CAMBRIDGE MA 02142
Robert Heft director 87 CAMBRIDGEPARK DRIVE, C/O RA PHARMACEUTICALS, INC., CAMBRIDGE MA 02140
Patrick J Kerins 10 percent owner
Ra Capital Management, L.p. director, 10 percent owner 200 BERKELEY STREET, 18TH FLOOR, BOSTON MA 02116
Ra Capital Healthcare Fund Lp director, 10 percent owner 200 BERKELEY STREET, 18TH FLOOR, BOSTON MA 02116
David Charles Lubner officer: Executive VP and CFO C/O TETRAPHASE PHARMACEUTICALS, INC., 480 ARSENAL STREET, SUITE 110, WATERTOWN MA 02472

Ra Pharmaceuticals (Ra Pharmaceuticals) Headlines

From GuruFocus

4 Stocks With More Than 20% Price Increases on Thursday

By James Li James Li 10-10-2019